Eyenovia Q2 net loss $11.1M; plans Gen-2 Optejet submission 2025 with Mydcombi

HYPERION DEFI, INC.

2024-Q2 EPS reported -$0.44 revenue$27,618

Net loss $11.1M ($0.21/share) vs $6.2M ($0.16/share) in Q2 2023; includes $2.9M MicroPine license reacquisition expense.
Cash $2.3M at June 30; $5.8M gross equity proceeds after quarter; expects funding through Phase 3 CHAPERONE data.
Following FDA meeting, plans Gen-2 Optejet validation in Q4 2024 and regulatory submission 2025 with Mydcombi as lead.
Phase 3 CHAPERONE study of MicroPine; analysis expected Q4 2024.
Mydcombi launched in 63 new offices; targeting 263 by Q3 end; dry eye collaborations with Formosa, Senju, SGN.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.